Adverum Biotech (ADVM) is Downgraded by Chardan Capital Markets to Neutral, Price Target at $5

Adverum Biotech (ADVM) was Downgraded by Chardan Capital Markets to ” Neutral” and the brokerage firm has set the Price Target at $5. Earlier the firm had a rating of “Buy ” on the company shares. Chardan Capital Markets advised their investors in a research report released on Jun 8, 2016.

Adverum Biotech

Leave a Reply

Adverum Biotech - Is it time to Sell?

Top Brokerage Firms are advising their investors on Adverum Biotech. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.